Market history · from the 250-topic plan

Pricing archaeology: how the shortage era built the $99 door — and what its fossils still sell

Stratum 1: the shortage that opened the door (2022–2024)

Compounding law contains a pressure valve: when a drug sits on FDA's shortage list, compounders may prepare copies of it at meaningful scale — outsourcing facilities included — because patients need medicine that manufacturers can't supply. Semaglutide entered the list in 2022 with tirzepatide following, as demand outran the pens; the valve opened, and an industry walked through it. Everything about the era's marketing — “same active ingredient,” volume pricing, subscription funnels — was built on that temporary legal floor, a fact the marketing rarely footnoted.

Stratum 2: the land grab and the birth of the door

With supply legal and demand bottomless, the binding constraint became customer acquisition — and pricing behaved accordingly: doors priced below sustainable unit economics ($99 first months, ninety-dollar-something semaglutide promos), renewal corridors doing the real earning, and two-line structures keeping headline numbers small. None of this was mysterious; it was venture-style growth math applied to prescriptions. The era's pricing instruments — qualifiers, promo annualization gaps, per-vial ambiguity — are all artifacts of acquiring customers faster than economics could bill them honestly.

Stratum 3: resolution and wind-down (Dec 2024 – mid 2025)

The floor moved: FDA declared tirzepatide's shortage resolved in December 2024 and semaglutide's in early 2025, with staggered grace periods ending scale-copying — traditional 503A pharmacies first, outsourcing facilities weeks later, completing through the first half of 2025. The market bifurcated on contact: operators built on the shortage valve alone faced exits, pivots, or the gray zone; operators built on patient-specific practice continued under the law's ordinary lane. A wave of “is compounded semaglutide banned now?” confusion dates to this stratum — the answer then and now being no, but the legal basis narrowed, which is a different sentence than either side's marketing preferred.

Stratum 4: the current basis — and the layer forming above it

Post-wind-down legitimacy rests where the legal stack put it: a named patient, a valid prescription, a documented clinical rationale for the compounded version, a pharmacy licensed for your state. Above it, the next layer is visibly forming: FDA's April 2026 proposal on compounded GLP-1s took public comment through July 30, 2026, and — as of this article's date — no final rule has issued. This site's discipline about that: we describe proposals as proposals, we don't trade on regulatory predictions, and this page carries a dateline precisely because stratum four is still wet.

Reading today's fossils

The archaeology cashes out as three shopping skills. Date every price: “cheapest tirzepatide” lists citing land-grab-era doors are quoting extinct strata — our dataset prints verification dates because a price without a date is a rumor with typography. Read doors as fossils: a below-economics first month in 2026 is either a funded acquisition bet or a corner being cut somewhere less visible; annualize before admiring. Prize stratum-four architecture: programs whose model was always patient-specific — audited pricing, named pharmacies, documented rationale, published exits — didn't need the shortage and didn't wobble when it closed; that continuity is itself due diligence, and it's what the field's audited benchmark was selected for. Built for stratum four ↗

FAQ

Why was compounded semaglutide so cheap in 2023–2024?

Shortage listings legalized scale copying while customer acquisition set prices — doors ran below unit economics with renewal corridors doing the earning; many of those prices are extinct strata still quoted by stale listicles.

Is compounded GLP-1 medication still legal after the shortages ended?

Yes, on a narrower basis: patient-specific prescriptions with documented clinical rationale, via properly licensed pharmacies — the scale-copying valve closed with the 2024–2025 resolutions and wind-downs.

What is the 2026 FDA proposal about?

An April 2026 proposal addressing compounded GLP-1s took comment through July 30, 2026; no final rule has issued as of this writing — treat predictions about it as marketing.

How do I avoid stale GLP-1 pricing online?

Demand dates: verified-on dates per price, annualized renewals rather than doors, and providers whose model predates and survives the shortage era.

Sources

• FDA shortage-list history for semaglutide and tirzepatide; resolution announcements (Dec 2024; early 2025) and staggered wind-down deadlines.
• FD&C Act compounding provisions — the shortage valve and the patient-specific lane.
• FDA's April 2026 proposed rulemaking and comment docket (closed July 30, 2026).
• This site's dated audit records — the open dataset.